Patents matching “formulation”

US 9238692

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jan 19, 2016 · Expires Jan 14, 2036

US 9233164

Water soluble fullerene formulations and methods of use thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jan 12, 2016 · Expires Jan 7, 2036

US 9216178

Dry blend formulation of tetrahydrobiopterin

BIOMARIN PHARMACEUTICAL INC. · Granted Dec 22, 2015 · Expires Dec 17, 2035

US 2015359783

PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF

BIAL PORTELA & Cª S A [PT] · Granted Dec 17, 2015 · Expires Dec 12, 2035

US 9212273

Elastomer formulations

MOLECULAR REBAR DESIGN, LLC · Granted Dec 15, 2015 · Expires Dec 10, 2035

WO 2015187736

FORMULATIONS PLACEBO ET UTILISATIONS DE CELLES-CI

ALLERGEN RES CORP [US] · Granted Dec 10, 2015 · Expires Dec 5, 2035

US 9200090

Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

GALECTIN THERAPEUTICS, INC. · Granted Dec 1, 2015 · Expires Nov 26, 2035

US 9193801

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Nov 24, 2015 · Expires Nov 19, 2035

US 9192644

Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders

The Regents of the University of California · Granted Nov 24, 2015 · Expires Nov 19, 2035

US 9186413

Sustained delivery formulations of risperidone compounds

Indivior UK Limited · Granted Nov 17, 2015 · Expires Nov 12, 2035

US 9180097

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Nov 10, 2015 · Expires Nov 5, 2035

US 9180197

Sustained delivery formulations of risperidone compounds

Indivior UK Limited · Granted Nov 10, 2015 · Expires Nov 5, 2035

US 9173880

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Nov 3, 2015 · Expires Oct 29, 2035

US 9161984

Formulations and methods of use for alpha connexin C-terminal (ACT) peptides

FIRSTSTRING RESEARCH, INC. · Granted Oct 20, 2015 · Expires Oct 15, 2035

US 9144551

Drug formulations having reduced abuse potential

Supernus Pharmaceuticals, Inc. · Granted Sep 29, 2015 · Expires Sep 24, 2035

US 2015265529

ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS

ALKERMES PHARMA IRELAND LTD [IE] · Granted Sep 24, 2015 · Expires Sep 19, 2035

US 9138479

Formulations for the treatment of diabetes

XERIS PHARMACEUTICALS, INC. · Granted Sep 22, 2015 · Expires Sep 17, 2035

US 9132087

Auris formulations for treating otic diseases and conditions

The Regents of the University of California · Granted Sep 15, 2015 · Expires Sep 10, 2035

US 9125805

Stable formulations for parenteral injection of small molecule drugs

XERIS PHARMACEUTICALS, INC. · Granted Sep 8, 2015 · Expires Sep 3, 2035

US 9125833

Multimodal abuse resistant and extended release opioid formulations

Relmada Therapeutics, Inc. · Granted Sep 8, 2015 · Expires Sep 3, 2035

US 9120031

Compositions of particulate coformulation

Nektar Therapeutics · Granted Sep 1, 2015 · Expires Aug 27, 2035

US 9119773

Toroidal pharmaceutical formulations

The Board of Regents of the University of Texas System · Granted Sep 1, 2015 · Expires Aug 27, 2035

US 9119823

Nitrite formulations and their use as nitric oxide prodrugs

The Board of Regents of the University of Texas System · Granted Sep 1, 2015 · Expires Aug 27, 2035

US 9114145

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Aug 25, 2015 · Expires Aug 20, 2035